Sugi Predict

Sugi Predict / Compounds / SCHEMBL969732

SCHEMBL969732

SCHEMBL969732

Oc1c(-c2nnc(Cc3ccc(F)cc3)o2)nc(-c2ccccc2)c2cccnc12

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.44
▸ NPC1 O15118 5/20 0.44
▸ HPGD P15428 3/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ TSHR P16473 2/20 0.44
▸ GPR55 Q9Y2T6 1/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.40
▸ POLB P06746 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ APLNR P35414 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ PARP1 P09874 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL968387 0.93 SMN1; SMN2 (0.44) RAB9ANPC1HPGDSMN1; SMN2TSHR
SCHEMBL966296 0.91 NPC1 (0.42) RAB9ANPC1HPGDSMN1; SMN2TSHR
SCHEMBL967551 0.91 NPC1 (0.57) RAB9ANPC1HPGDSMN1; SMN2TSHR
SCHEMBL966977 0.91 NPC1 (0.42) RAB9ANPC1HPGDSMN1; SMN2TSHR
SCHEMBL966861 0.89 NPC1 (0.43) RAB9ANPC1HPGDSMN1; SMN2TSHR
SCHEMBL967385 0.89 NPC1 (0.42) RAB9ANPC1HPGDSMN1; SMN2TSHR
SCHEMBL966724 0.89 RAB9A (0.42) RAB9ANPC1HPGDSMN1; SMN2TSHR
SCHEMBL967419 0.89 NPC1 (0.42) RAB9ANPC1HPGDSMN1; SMN2TSHR
SCHEMBL969393 0.89 NPC1 (0.40) RAB9ANPC1HPGDSMN1; SMN2TSHR
SCHEMBL968926 0.88 HDAC6 (0.39) RAB9ANPC1HPGDSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003794-A1 Naphthyridine Integrase Inhibitors GSK LLC 2011-01-06 — — US disclosed
US-20110003794-A1 Naphthyridine Integrase Inhibitors GSK LLC 2011-01-06 — — US disclosed
US-20110003794-A1 Naphthyridine Integrase Inhibitors GSK LLC 2011-01-06 — — US disclosed
US-7812016-B2 Naphthyridine integrase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-10-12 — — US disclosed
US-7812016-B2 Naphthyridine integrase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-10-12 — — US disclosed
US-7812016-B2 Naphthyridine integrase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-10-12 — — US disclosed
US-20070142365-A1 Naphthyridine integrase inhibitors GSK LLC 2007-06-21 — — US disclosed
US-20070142365-A1 Naphthyridine integrase inhibitors GSK LLC 2007-06-21 — — US disclosed
US-20070142365-A1 Naphthyridine integrase inhibitors GSK LLC 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003794-A1 Naphthyridine Integrase Inhibitors PCNA, SAMHD1, NTPCR RAB9A 2668/4885NPC1 220/4885HPGD 1538/4885
US-20070142365-A1 Naphthyridine integrase inhibitors PCNA, SAMHD1, NTPCR RAB9A 2668/4885NPC1 220/4885HPGD 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.